title: Pharmacological treatment of disruptive behavior in children with fetal alcohol spectrum disorder.
abstract: Fetal alcohol spectrum disorder (FASD) is considered to be the most common cause of developmental disability, affecting more than 1% of the general population in North America. Inattention, hyperactivity, and impulsivity afflict 50-90% of children with FASD and are 3-9 times more common than in the general population. Of importance, a large proportion of children with FASD are affected by oppositional defiant/conduct disorder (ODD/CD), including lack of social judgment and failure to learn from experience. These devastating numbers are contrasted by almost no pharmacological research into treatment of these pervasive conditions in FASD. This review focuses on analyzing the published evidence on the effectiveness and safety of therapy for disruptive behaviors in FASD. Often, the child afflicted by FASD will not be allowed to participate in class activities without such therapies, which makes such analysis critical.
authors: Motherisk Program, Division of Clinical Pharmacology/Toxicology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada, gkoren@sickkids.ca.
authors: Gideon
authors: G
authors: Koren
mesh_terms: D002648:Child; D063647:Fetal Alcohol Spectrum Disorders / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000066553:Problem Behavior
references: Neuropsychiatr Dis Treat. 2014 Sep 26;10:1781-91
references: 25298735
references: J Child Adolesc Psychopharmacol. 2008 Aug;18(4):365-71
references: 18759646
references: J Toxicol Environ Health A. 2004 Dec;67(23-24):2073-84
references: 15513904
references: Brain Cogn. 2007 Oct;65(1):135-42
references: 17669569
references: Pediatrics. 2014 Nov;134(5):855-66
references: 25349310
references: Can J Psychiatry. 2000 Feb;45(1):90-1
references: 10696504
references: Community Ment Health J. 2015 Aug;51(6):738-45
references: 25179388
references: Can J Psychiatry. 2002 May;47(4):349-54
references: 12025433
references: J Child Adolesc Psychopharmacol. 1998;8(1):39-48
references: 9639078
references: Alcohol Clin Exp Res. 2000 Feb;24(2):226-31
references: 10698376
references: Can J Psychiatry. 2010 May;55(5):305-12
references: 20482957
references: Nutr Res. 2013 Nov;33(11):897-904
references: 24176229
references: Can J Psychiatry. 2012 Dec;57(12):717-21
references: 23228229
references: J Child Adolesc Psychopharmacol. 2006 Dec;16(6):777-89
references: 17201621
references: Mater Sociomed. 2014 Aug;26(4):253-5
references: 25395888
references: CNS Spectr. 2004 Mar;9(3):217-26
references: 14999162
references: Can J Psychiatry. 2013 Jun;58(6):361-9
references: 23768264
references: Dev Sci. 2005 Mar;8(2):122-31
references: 15720370
references: Am J Drug Alcohol Abuse. 2002 Nov;28(4):743-54
references: 12492268
references: J Clin Psychopharmacol. 2014 Oct;34(5):613-9
references: 25154009
references: J Dev Behav Pediatr. 2004 Aug;25(4):228-38
references: 15308923
references: Am J Psychiatry. 1998 Apr;155(4):552-4
references: 9546004
references: Int Rev Neurobiol. 2014;118:41-80
references: 25175861
references: Alcohol Clin Exp Res. 2005 Aug;29(8):1359-67
references: 16131842
references: Psychopharmacology (Berl). 2007 Mar;191(1):127-40
references: 16983542
references: Can J Psychiatry. 2012 Dec;57(12):722-7
references: 23228230
references: Alcohol Clin Exp Res. 2004 Nov;28(11):1732-45
references: 15547461
references: Biol Psychiatry. 2014 Oct 15;76(8):616-28
references: 24314347
references: J Am Acad Child Adolesc Psychiatry. 1993 Sep;32(5):990-4
references: 8407775
references: J Clin Exp Neuropsychol. 2011 Aug;33(7):805-19
references: 21598155
references: Dtsch Arztebl Int. 2014 Jan 17;111(3):25-34
references: 24606780
references: J Nutr Biochem. 2013 May;24(5):760-9
references: 22841392
references: Birth Defects Res C Embryo Today. 2014 Sep;102(3):210-20
references: 25219761